Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0851
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy ; day:6 ; month:3 ; year:2020 ; pages:1-14
Cancer immunology immunotherapy ; (6.3.2020), 1-14
- Urheber
-
Voloshin, Tali
Kaynan, Noa
Davidi, Shiri
Porat, Yaara
Shteingauz, Anna
Schneiderman, Rosa S.
Zeevi, Einav
Munster, Mijal
Blat, Roni
Tempel Brami, Catherine
Cahal, Shay
Itzhaki, Aviran
Giladi, Moshe
Kirson, Eilon D.
Weinberg, Uri
Kinzel, Adrian
Palti, Yoram
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00262-020-02534-7
- URN
-
urn:nbn:de:101:1-2020052622104350763350
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Voloshin, Tali
- Kaynan, Noa
- Davidi, Shiri
- Porat, Yaara
- Shteingauz, Anna
- Schneiderman, Rosa S.
- Zeevi, Einav
- Munster, Mijal
- Blat, Roni
- Tempel Brami, Catherine
- Cahal, Shay
- Itzhaki, Aviran
- Giladi, Moshe
- Kirson, Eilon D.
- Weinberg, Uri
- Kinzel, Adrian
- Palti, Yoram
- SpringerLink (Online service)
Ähnliche Objekte (12)
Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system
In situ chemoimmunotherapy hydrogel elicits immunogenic cell death and evokes efficient antitumor immune response
RIG-I-induced antitumor immunity is driven by immunogenic tumor cell-derived extracellular vesicles
Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1
Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA
Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming
Neoantigen-augmented iPSC cancer vaccine combined with radiotherapy promotes antitumor immunity in poorly immunogenic cancers
Enhanced efficacy of combined VEGFR peptide–drug conjugate and anti-PD-1 antibody in treating hepatocellular carcinoma
Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma
Targeted inhibition of SCFSKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma
Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8+T cells for systemic antitumor responses
Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system
In situ chemoimmunotherapy hydrogel elicits immunogenic cell death and evokes efficient antitumor immune response
RIG-I-induced antitumor immunity is driven by immunogenic tumor cell-derived extracellular vesicles
Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1
Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA
Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming
Neoantigen-augmented iPSC cancer vaccine combined with radiotherapy promotes antitumor immunity in poorly immunogenic cancers
Enhanced efficacy of combined VEGFR peptide–drug conjugate and anti-PD-1 antibody in treating hepatocellular carcinoma
Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma
Targeted inhibition of SCFSKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma
Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8+T cells for systemic antitumor responses
Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system
In situ chemoimmunotherapy hydrogel elicits immunogenic cell death and evokes efficient antitumor immune response
RIG-I-induced antitumor immunity is driven by immunogenic tumor cell-derived extracellular vesicles
Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1
Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA
Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming
Neoantigen-augmented iPSC cancer vaccine combined with radiotherapy promotes antitumor immunity in poorly immunogenic cancers
Enhanced efficacy of combined VEGFR peptide–drug conjugate and anti-PD-1 antibody in treating hepatocellular carcinoma
Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma
Targeted inhibition of SCFSKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma